Cargando…

Medicinal Components in Edible Mushrooms on Diabetes Mellitus Treatment

Mushrooms belong to the family “Fungi” and became famous for their medicinal properties and easy accessibility all over the world. Because of its pharmaceutical properties, including anti-diabetic, anti-inflammatory, anti-cancer, and antioxidant properties, it became a hot topic among scientists. Ho...

Descripción completa

Detalles Bibliográficos
Autores principales: Das, Arpita, Chen, Chiao-Ming, Mu, Shu-Chi, Yang, Shu-Hui, Ju, Yu-Ming, Li, Sing-Chung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8875793/
https://www.ncbi.nlm.nih.gov/pubmed/35214168
http://dx.doi.org/10.3390/pharmaceutics14020436
_version_ 1784658017515470848
author Das, Arpita
Chen, Chiao-Ming
Mu, Shu-Chi
Yang, Shu-Hui
Ju, Yu-Ming
Li, Sing-Chung
author_facet Das, Arpita
Chen, Chiao-Ming
Mu, Shu-Chi
Yang, Shu-Hui
Ju, Yu-Ming
Li, Sing-Chung
author_sort Das, Arpita
collection PubMed
description Mushrooms belong to the family “Fungi” and became famous for their medicinal properties and easy accessibility all over the world. Because of its pharmaceutical properties, including anti-diabetic, anti-inflammatory, anti-cancer, and antioxidant properties, it became a hot topic among scientists. However, depending on species and varieties, most of the medicinal properties became indistinct. With this interest, an attempt has been made to scrutinize the role of edible mushrooms (EM) in diabetes mellitus treatment. A systematic contemporary literature review has been carried out from all records such as Science Direct, PubMed, Embase, and Google Scholar with an aim to represents the work has performed on mushrooms focuses on diabetes, insulin resistance (IR), and preventive mechanism of IR, using different kinds of mushroom extracts. The final review represents that EM plays an important role in anticipation of insulin resistance with the help of active compounds, i.e., polysaccharide, vitamin D, and signifies α-glucosidase or α-amylase preventive activities. Although most of the mechanism is not clear yet, many varieties of mushrooms’ medicinal properties have not been studied properly. So, in the future, further investigation is needed on edible medicinal mushrooms to overcome the research gap to use its clinical potential to prevent non-communicable diseases.
format Online
Article
Text
id pubmed-8875793
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88757932022-02-26 Medicinal Components in Edible Mushrooms on Diabetes Mellitus Treatment Das, Arpita Chen, Chiao-Ming Mu, Shu-Chi Yang, Shu-Hui Ju, Yu-Ming Li, Sing-Chung Pharmaceutics Review Mushrooms belong to the family “Fungi” and became famous for their medicinal properties and easy accessibility all over the world. Because of its pharmaceutical properties, including anti-diabetic, anti-inflammatory, anti-cancer, and antioxidant properties, it became a hot topic among scientists. However, depending on species and varieties, most of the medicinal properties became indistinct. With this interest, an attempt has been made to scrutinize the role of edible mushrooms (EM) in diabetes mellitus treatment. A systematic contemporary literature review has been carried out from all records such as Science Direct, PubMed, Embase, and Google Scholar with an aim to represents the work has performed on mushrooms focuses on diabetes, insulin resistance (IR), and preventive mechanism of IR, using different kinds of mushroom extracts. The final review represents that EM plays an important role in anticipation of insulin resistance with the help of active compounds, i.e., polysaccharide, vitamin D, and signifies α-glucosidase or α-amylase preventive activities. Although most of the mechanism is not clear yet, many varieties of mushrooms’ medicinal properties have not been studied properly. So, in the future, further investigation is needed on edible medicinal mushrooms to overcome the research gap to use its clinical potential to prevent non-communicable diseases. MDPI 2022-02-17 /pmc/articles/PMC8875793/ /pubmed/35214168 http://dx.doi.org/10.3390/pharmaceutics14020436 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Das, Arpita
Chen, Chiao-Ming
Mu, Shu-Chi
Yang, Shu-Hui
Ju, Yu-Ming
Li, Sing-Chung
Medicinal Components in Edible Mushrooms on Diabetes Mellitus Treatment
title Medicinal Components in Edible Mushrooms on Diabetes Mellitus Treatment
title_full Medicinal Components in Edible Mushrooms on Diabetes Mellitus Treatment
title_fullStr Medicinal Components in Edible Mushrooms on Diabetes Mellitus Treatment
title_full_unstemmed Medicinal Components in Edible Mushrooms on Diabetes Mellitus Treatment
title_short Medicinal Components in Edible Mushrooms on Diabetes Mellitus Treatment
title_sort medicinal components in edible mushrooms on diabetes mellitus treatment
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8875793/
https://www.ncbi.nlm.nih.gov/pubmed/35214168
http://dx.doi.org/10.3390/pharmaceutics14020436
work_keys_str_mv AT dasarpita medicinalcomponentsinediblemushroomsondiabetesmellitustreatment
AT chenchiaoming medicinalcomponentsinediblemushroomsondiabetesmellitustreatment
AT mushuchi medicinalcomponentsinediblemushroomsondiabetesmellitustreatment
AT yangshuhui medicinalcomponentsinediblemushroomsondiabetesmellitustreatment
AT juyuming medicinalcomponentsinediblemushroomsondiabetesmellitustreatment
AT lisingchung medicinalcomponentsinediblemushroomsondiabetesmellitustreatment